5-n-Butyl-pyridin-2-carbonsaeurechlorid | 67261-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-n-Butyl-pyridin-2-carbonsaeurechlorid
• 英文别名: 5-butylpicolinoyl chloride；fusaric acid chloride；Fusarsaeurechlorid；5-Butylpyridine-2-carbonyl chloride
• CAS: 67261-92-1
• 化学式: C₁₀H₁₂ClNO
• 分子量: 197.664
• InChiKey: HWERRMFMCWTKCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-n-Butyl-pyridin-2-carbonsaeurechlorid 生成 [4-(4-pentoxyphenoxy)carbonylphenyl] 5-butylpyridine-2-carboxylate
  参考文献：
  名称：

  DEMUS, D.;ZASCHKE, H.;PASCHKE, R.;WIEGELEBEN, A.

  摘要：

  DOI：
• 作为产物：
  描述：

  5-丁基吡啶-2-羧酸 在 氯化亚砜 作用下， 生成 5-n-Butyl-pyridin-2-carbonsaeurechlorid
  参考文献：
  名称：

  Mesomorphic compound, liquid crystal composition containing same, liquid

  摘要：

  一种由以下化学式（I）表示的中间体化合物：R.sub.1 --A.sub.1 --B.sub.1 --A.sub.2 --R.sub.2（I），其中R.sub.1和R.sub.2分别表示具有3-18个碳原子的线性或支链烷基基团，可包括一个或非相邻的两个或更多个亚甲基基团，该亚甲基基团可被至少一种##STR1##所替代，其中Z表示--O--或--S--，R.sub.3表示氢或具有1-5个碳原子的烷基基团；B.sub.1表示##STR2##；A.sub.1表示一个单键，##STR3##；A.sub.2表示一个单键，--A.sub.3 --或--A.sub.3 --A.sub.4 --其中A.sub.3和A.sub.4分别表示##STR4##，Y.sub.1和Y.sub.2分别表示氢、氟、氯、溴、--CH.sub.3、--CN和--CF.sub.3中的任意一种。

  公开号：

  US05236619A1

文献信息

• Isoindole-imide compounds and compositions comprising and methods of using the same
  申请人：Muller W. George

  公开号：US20070049618A1

  公开（公告）日：2007-03-01

  This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  这项发明涉及异吲哚-亚胺化合物，以及它们的药物可接受的盐、溶剂化物、对映异构体和前药。这些化合物的使用方法和药物组合物已经公开。
• [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE<br/>[FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011080718A1

  公开（公告）日：2011-07-07

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。
• INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120289505A1

  公开（公告）日：2012-11-15

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体；以及它们的药学上可接受的盐，药学上可接受的溶剂化合物和药学上可接受的多晶形态。本发明还涉及制造这些杂环化合物的方法以及含有它们的制药组合物。所述化合物及其制药组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，尤其是DGAT1。本发明还提供了一种通过向需要治疗的哺乳动物中给予所述化合物或其制药组合物的治疗方法来治疗这些疾病或紊乱的方法。
• CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120214854A1

  公开（公告）日：2012-08-23

  Heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase (DGAT) enzyme, particularly DGAT-1 is described.

  本文描述了杂环芳基化合物的制备方法、含有它们的制药组合物，以及它们在治疗由Diacylglycerol acyltransferase (DGAT)酶介导的疾病或紊乱中的应用，特别是DGAT-1。
• Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity
  申请人：Jadhav Ravindra Dnyandev

  公开号：US08722901B2

  公开（公告）日：2014-05-13

  Heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase (DGAT) enzyme, particularly DGAT-1 is described.

  本发明涉及杂环芳基化合物，其制备方法，包含它们的制药组合物及其在治疗由Diacylglycerol acyltransferase（DGAT）酶介导的疾病或疾病中的应用，特别是DGAT-1。